This non-promotional, sponsored webinar will review health plan best practice recommendations for Chronic Lymphocytic Leukemia (CLL) with an impressive panel of oncology and managed care experts.

As managed care and payer professionals play a central role in improving value in and access to cancer care, understanding best practices in CLL that address the multidimensional system challenges can support identifying which health services are safe, efficacious, and cost-effective, address barriers to high-quality care, and better understand the patient experience in the health care system.

In this webinar, a panel of experts will discuss health plan best practices related to CLL, national managed care oncology professional survey results, and components of high-quality care that can improve health equity and address unmet needs in CLL. Following the presentation, join the panelists for a live Q&A session.

In this webinar, a panel of experts discuss health plan best practices related to continuous glucose monitoring. Following the presentation, join the panelists for a live Q&A session.

Learn About:

At the completion of this activity, participants should be able to:

• Explore health plan practices for the treatment of CLL
• Discuss key insights from a national managed care oncology survey on the treatments for CLL
• Examine strategies available to managed care professionals to guide treatment for CLL
• Identify components of high-quality care that improve health equity and address unmet needs in cancer care

This webinar explores the evolution of the treatment landscape, clinical outcomes, and practical management of a BCL2-Inhibitor. The content of this webinar is intended for US Formulary Decision Makers.

Learning Objectives:

• Review the AML disease state and evolving treatment landscape.
• Describe the efficacy and safety of BCL2-inhibitor treatment in newly diagnosed AML unfit for intensive chemotherapy.
• Provide an overview of the practical management of AML patients receiving BCL2-inhibitor treatment.

This expert-led webinar will explore the state of HCV in the United States, testing and treatment recommendations, key barriers to HCV treatment access and their impacts, how payers benefit from expanding HCV treatment access, treatment considerations for today's complex HCV population, and a treatment option that addresses many of the needs of today's patient population.

Nearly a decade after the development of direct-acting antiviral treatments that can cure HCV in more than 95% of people infected, only a small fraction of the 2.5 million people with chronic HCV in the United States have received treatment, and tens of thousands still die from the disease every year. This expert-led webinar will highlight:

• How many people in the United States have HCV and what percentage are diagnosed and treated
• Which patients are currently most likely to be infected with HCV
• HCV screening and treatment recommendations from major medical organizations
• Major barriers to HCV treatment and which patients are most impacted by them
• Benefits for payers of expanding HCV treatment access
• Important treatment considerations for today's complex chronic HCV patient population, including common comorbidities, concomitant medications, and lifestyle factors
• A treatment option for HCV that addresses many of the needs of today's patient population

Crohn’s Disease is a chronic, progressive, inflammatory bowel disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability.  The American Gastroenterological Association treatment guidelines for moderate to severe Crohn’s Disease have been updated and new long-term goals for the management of the disease have been established.

Clinical advancement of the treatment of moderate to severe Crohn’s Disease have included therapeutic options with diverse mechanisms of action.  Head-to-head trials play an important role in advancing the science for HCPs and HCDMs responsible for the treatment of patients with Crohn’s Disease.  The SEQUENCE trial design consisted of randomizing patients with moderate to severe CD who have failed TNF therapy to two treatments arms, an IL-23 inhibitor and an IL-12/23 inhibitor with a goal of assessing both clinical and endoscopic endpoints.

Approximately 5%-10% of all asthma patients in the US have severe asthma. Patients with severe asthma who are uncontrolled are at risk for oral corticosteroid dependence, exacerbations, and progressive loss of lung function. Clinical remission has been proposed as a new target for patients with severe asthma with the goal of slowing or stopping disease progression. The concept of clinical remission takes a more holistic view of the disease in that it includes achieving a combination of parameters and not a single endpoint such as symptom relief. Similar to the evolution observed with other inflammatory disease states, such as rheumatoid arthritis, availability of new therapies allows for the consideration as to whether clinical remission is an achievable treatment target in severe asthma. This program will provide disease education for population-based decision makers to inform on the concept of clinical remission and next steps in elevating clinical remission as a goal for asthma.

Objectives:

• Describe the evolution of clinical remission as a target in other chronic inflammatory diseases  
• Share perspective of the value of achieving clinical remission, for patients with severe asthma, including improvements in daily life and long-term outcomes
• Define components of clinical remission for severe asthma and trajectory of this goal

The objective for this webinar, conducted by Abbvie Medical Affairs, is to review the migraine disease state and discuss the treatment landscape, with a focus on an acute treatment option.

Endometriosis is a chronic, estrogen-dependent inflammatory disease characterized by chronic pelvic pain and infertility, that can have a significant impact in some patients on quality of life, function, and healthcare costs.  The total annual societal burden of endometriosis in the United States is estimated to be $69.4 billion, of which indirect and direct costs comprise 66% and 34%, respectively.  Endometriosis disease peaks at the most productive working- years and contributes to a loss of 1.1 hours per week of employment productivity because of absenteeism and an average loss of 5.3 hours per week due to presenteeism.  Therefore, early diagnosis and treatment is crucial for the best outcome and relief of symptoms. 

The objective of this webinar is to understand the burden of endometriosis and its impact on quality of life, which is essential to developing an individualized treatment approach to address each patient’s unique needs.  Additionally, we will review the current treatment landscape as well as data from a clinical trial program for endometriosis associated pain.